Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03213041
Title Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.